Beijing Konruns Pharmaceutical Co (SHSE:603590) ROCE % : 5.01% (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Beijing Konruns Pharmaceutical Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Beijing Konruns Pharmaceutical Co's annualized ROCE % for the quarter that ended in Sep. 2024 was 5.01%.

Beijing Konruns Pharmaceutical Co ROCE % Historical Data

The historical data trend for Beijing Konruns Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Konruns Pharmaceutical Co ROCE % Chart

Beijing Konruns Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

8.87

6.91

5.93

4.34

3.73

Beijing Konruns Pharmaceutical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															7.84	-7.31	5.88	5.83	5.01

Beijing Konruns Pharmaceutical Co ROCE % Calculation

Beijing Konruns Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	125.127	/	( ( (3424.801 - 172.363)	+	(3780.818 - 323.387) )	/ 2 )
	=	125.127	/	( (3252.438	+	3457.431)	/ 2 )
	=	125.127	/	3354.9345
	=	3.73 %

Beijing Konruns Pharmaceutical Co's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	181.232	/	( ( (3908.494 - 354.744)	+	(3996.056 - 319.471) )	/ 2 )
	=	181.232	/	( ( 3553.75	+	3676.585 )	/ 2 )
	=	181.232	/	3615.1675
	=	5.01 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Beijing Konruns Pharmaceutical Co (SHSE:603590) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Beijing Konruns Pharmaceutical Co ROCE % Related Terms

Thank you for viewing the detailed overview of Beijing Konruns Pharmaceutical Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Konruns Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Konruns Pharmaceutical Co Ltd (SHSE:603590) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 11 Xingsheng South Road, Economic Development Zone, Miyun District, Beijing, CHN

Website

http://www.konruns.cn

Beijing Konruns Pharmaceutical Co Ltd is a Chinese pharmaceutical company. It is engaged in the research and development of innovative drugs, and is oriented to clinical needs.

Executives

Feng Zhang Zheng

Director

Beijing Konruns Pharmaceutical Co Headlines

No Headlines